News | July 04, 2025
Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
The company has confirmed that the deceased are 39
A triple-action Formula for comprehensive respiratory relief
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
mRNA-1010 demonstrated superior relative vaccine efficacy
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Subscribe To Our Newsletter & Stay Updated
